April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Current Prognoses With Metastatic Renal Cell Carcinoma
Before closing out their review of the first clinical scenario, panelists consider the general state of prognoses within metastatic renal cell carcinoma.
Dose Adjusting Therapy for Patients With Metastatic Renal Cell Carcinoma
A brief review of dose hold or adjustment strategies in the setting of metastatic renal cell carcinoma and when it is appropriate to consider these options.
Metastatic Renal Cell Carcinoma: Communicating Treatment Options With Patients
Shared insight on the treatment armamentarium for metastatic renal cell carcinoma and how these options should be communicated with patients.
Clinical Scenario 1: Renal Cell Carcinoma Diagnosis and Staging
Centering discussion on a clinical scenario of metastatic renal cell carcinoma, expert panelists reflect on optimal diagnosis and stratification methods in this setting.
AI-Based Model May Guide Decision-Making in Kidney Cancer Based on CT, EGFR
March 17th 2023Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCC
March 14th 2023Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer Subtype
March 12th 2023Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Expert Highlights Armamentarium of Advanced Kidney Cancer Therapies
March 11th 2023An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Nivolumab Combo Yields PFS Benefit Regardless of PD-L1, c-MET status in RCC
February 21st 2023An ongoing exploratory biomarker analysis of the CheckMate 9ER trial set out to identify predictive biomarkers or a composite model of response of nivolumab/cabozantinib efficacy in advanced renal cell carcinoma.
TFS Improves With Nivolumab, Salvage Nivolumab in Advanced Renal Cell Carcinoma
February 21st 2023Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.